Madrigal Pharmaceuticals, Inc. announced an exclusive global licensing agreement to introduce six preclinical-stage siRNA (small interfering RNA) programs, aiming to significantly expand its research and development pipeline for metabolic dysfunction-associated steatohepatitis (MASH).
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
This agreement further consolidates Madrigal's strategic positioning in the MASH treatment field.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
Hyperliquid yesterday reported a revenue of $3.27 million, reaching a new high since February 7th.
BlockBeats•2026/04/17 10:20
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$75,711.48
+1.68%
Ethereum
ETH
$2,357.05
+0.99%
Tether USDt
USDT
$1
+0.01%
XRP
XRP
$1.44
+2.27%
BNB
BNB
$631.99
+1.91%
USDC
USDC
$0.9998
-0.00%
Solana
SOL
$88.24
+4.03%
TRON
TRX
$0.3244
-0.72%
Dogecoin
DOGE
$0.09847
+3.09%
Hyperliquid
HYPE
$44.01
-2.63%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now